News | October 27, 2022
Dabur India posts consolidated Q2 FY2023 PAT at Rs. 490.06 Cr
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.
The purpose of the conclave was to discuss the present situation of body-organ-eye donation in India and find solutions to the challenges ahead in future
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
